Novo Nordisk vs. Dr. Reddy’s: Liraglutide Patent Dispute Dismissed After 135 Days
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Novo Nordisk A/S v. Dr. Reddy’s Laboratories, Ltd. |
| Numéro de dossier | 1:23-cv-22112 (D.N.J.) |
| Tribunal | Tribunal fédéral de première instance pour le district du New Jersey |
| Durée | Nov 2023 – Mar 2024 135 days |
| Résultat | Rejeté sans préjudice |
| Brevets en cause | |
| Produits incriminés | Generic Liraglutide Solution Injection (18 mg/3 ml, 6 mg/ml) |
Aperçu du dossier
Les parties
⚖️ Demandeur
Danish multinational pharmaceutical company and global leader in diabetes care, holding an extensive patent portfolio covering GLP-1 receptor agonist therapies.
🛡️ Défendeur
Major Indian multinational generic pharmaceutical manufacturer with substantial ANDA filing activity across therapeutic categories.
Brevets en cause
This ANDA litigation involved two patents covering formulation or composition aspects of liraglutide injectable solution, essential to Novo Nordisk’s proprietary GLP-1 products. These patents are registered with the U.S. Patent and Trademark Office (USPTO) and protect specific technical innovations rather than just active pharmaceutical ingredients.
- • U.S. Patent No. 8,114,833 — covering formulation or composition aspects of liraglutide injectable solution
- • U.S. Patent No. 9,265,893 — covering related therapeutic or formulation innovations for liraglutide delivery
Développer un équivalent générique ?
Check if your generic drug formulation might infringe these or related patents before ANDA submission.
Le verdict et l'analyse juridique
Résultat
The case was **dismissed without prejudice** pursuant to a joint stipulation agreed upon by both Novo Nordisk and DRL. No damages were awarded, no injunctive relief was formally issued, and no judicial determination on patent validity or infringement was made on the merits. Each party agreed to bear its own attorneys’ fees and costs — a standard feature of negotiated pharmaceutical patent settlements.
Critically, the dismissal without prejudice means **neither party is legally barred from future litigation** on these patents should circumstances change.
Principales questions juridiques
From a Hatch-Waxman litigation standpoint, the preservation of DRL’s Paragraph IV certification is the most legally notable element of this dismissal. Under the Hatch-Waxman framework, a Paragraph IV certification asserts that listed patents are invalid, unenforceable, or not infringed by the ANDA product. By stipulating that DRL may **maintain** this certification, the parties have effectively acknowledged that the underlying patent challenge remains unresolved on the merits.
This structure is consistent with settlements that include a **licensed entry date** — where the generic manufacturer agrees to delay commercial launch until a negotiated date in exchange for a license, while nominal certification status is preserved for regulatory purposes. The specific terms of any such arrangement between Novo Nordisk and DRL were not disclosed in the public court record.
Analyse de la liberté d'exploitation (FTO)
Ce cas met en évidence les risques majeurs liés à la propriété intellectuelle dans le développement des médicaments génériques. Choisissez la prochaine étape :
📋 Comprendre l'impact de cette affaire
Découvrez les risques spécifiques et les implications de ce litige pour les préparations pharmaceutiques.
- View all related patents in the GLP-1 space
- See key players in liraglutide generics
- Understand formulation claim scope
🔍 Vérifier les risques liés à mon produit
Effectuez une analyse FTO complète pour votre propre formulation générique.
- Input your generic drug description or technical features
- L'IA identifie les brevets de formulation susceptibles de constituer un obstacle
- Get actionable FTO risk assessment report
Zone à haut risque
Liraglutide formulations (6 mg/ml concentration)
2 brevets dans cette affaire
Formulation & delivery innovations
Options de contournement
Limited for biologics/formulations
✅ Points clés à retenir
Early settlement in ANDA litigation can preserve commercial exclusivity without the cost and uncertainty of full trial.
Rechercher la jurisprudence ANDA associée →Maintaining Paragraph IV certification in settlement is a sophisticated drafting technique with regulatory consequences for generic entry.
Explore ANDA litigation precedents →Foire aux questions
U.S. Patent Nos. 8,114,833 and 9,265,893, both covering aspects of liraglutide recombinant solution injection formulated at 6 mg/ml concentration.
The parties reached a private resolution and jointly stipulated to dismissal. No court ruled on patent validity or infringement. Dismissal without prejudice preserves both parties’ future litigation rights.
DRL’s ANDA No. 214411 remains pending with Paragraph IV certification intact. Any confidential settlement terms — including authorized entry dates — will govern actual generic market entry timing, not the public court record.
Brand companies can protect themselves by building multi-layered patent portfolios, promptly filing infringement actions within 45 days of Paragraph IV notice, and strategically negotiating settlements that control generic market entry. Generic companies must conduct robust FTO and invalidity analysis before filing ANDAs to assess litigation risk.
Prêt à renforcer votre stratégie en matière de brevets pharmaceutiques ?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision in the pharmaceutical sector.
Références
- United States District Court for the District of New Jersey — Case 1:23-cv-22112
- Office américain des brevets et des marques — Centre des brevets
- U.S. Food & Drug Administration — ANDA Database
- Cornell Legal Information Institute — 35 U.S.C. § 271(e)(2)
- PatSnap — IP Intelligence for Pharmaceutical & Biotech
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.